shotsky ring - SportsID
During a live event, Claudine Isaacs, MD, and participants discuss using elacestrant or T-DXd after progression in ESR1-mutated metastatic breast cancer. For patients with ESR1 -mutated, hormone receptor (HR)-positive, HER2-low metastatic breast cancer, progression on initial CDK4/6 inhibitor-based therapy presents a key sequencing decision. Buy only from trusted suppliers and use genuine software.
Understanding the Context
Use a trusted public cloud which brings the benefit of enterprise-grade data security and privacy protection. Microsoft would like to work with your organization to help you optimize your Software Assets and get the right advisory services suited to your needs.